Combined Hepatocellular-Cholangiocarcinoma: A Clinical and Molecular Review
Seminars in Liver Disease · 01.12.2025 · 45 (04) · 476-486
DOI: 10.1055/a-2730-9074 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Seminars in Liver Disease, erschienen am 01.12.2025. Verfasst von Shaodian Xu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Team "Viruses, Hepatology, Cancer," Institut Mondor de Recherche Biomédicale, Université Paris-Est, Créteil, France. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Carcinoma, Hepatocellular, Liver Neoplasms, Bile Duct Neoplasms. Die Arbeit nennt 116 Literaturangaben. Gefördert von: Institut National Du Cancer.
Abstract (Originalsprache)
Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare primary liver malignancy characterized by the coexistence of both hepatocellular and biliary morphological differentiation. It is thought to represent less than 5% of all primary liver cancers and is associated with a dismal clinical course. Due to its rarity and inherent diagnostic challenges, consensus guidelines for the management of patients with cHCC-CCA are lacking, and treatments are usually extrapolated from HCC or CCA guidelines. This review provides an overview of the main clinical and histo-molecular features of cHCC-CCA, along with its diagnostic and therapeutic challenges. Technological advances have allowed researchers to progressively elucidate cHCC-CCA's unique biology and heterogeneity. Several major questions, however, remain, such as the cHCC-CCA cell of origin. Integration of multi-modal data and use of artificial intelligence provide interesting perspectives to further improve patient management; however, they will need to be carefully assessed and validated. A better definition and understanding of this entity will be key to further planning clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Team "Viruses, Hepatology, Cancer," Institut Mondor de Recherche Biomédicale, Université Paris-Est, Créteil, France.
- MINT-Hep, Mondor Integrative Hepatology, Créteil, France.
- Department of Pathology, Assistance Publique-Hôpitaux de Paris, Henri Mondor-Albert Chenevier University Hospital, Créteil, France.
Förderung
- Institut National Du Cancer
Zitieren
APA
Xu, S., & Calderaro, J. (2025). Combined Hepatocellular-Cholangiocarcinoma: A Clinical and Molecular Review. Seminars in Liver Disease, 45(04), 476-486. https://doi.org/10.1055/a-2730-9074
Vancouver
Xu S, Calderaro J. Combined Hepatocellular-Cholangiocarcinoma: A Clinical and Molecular Review. Seminars in Liver Disease. 2025;45(04):476-486. doi:10.1055/a-2730-9074
BibTeX
@article{Xu2025,
author = {Xu, Shaodian and Calderaro, Julien},
title = {Combined Hepatocellular-Cholangiocarcinoma: A Clinical and Molecular Review},
journal = {Seminars in Liver Disease},
year = {2025},
volume = {45},
number = {04},
pages = {476--486},
doi = {10.1055/a-2730-9074}
}
EUVIMED